Zydus Lifesciences Ltd.

Zydus Cadila has launched the bio-similar of Adalimumab -the world's largest selling therapy. Bio-similar, developed by the researchers at the Zydus Research Centre, has been approved by the Drug Controller General of India and will be marketed under the brand name, ‘Exemptia’ to treat auto immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and Ankylosing  Spondylitis.

This novel non-infringing process for Adalimumab and a novel non-infringing formulation has been researched, developed and produced by scientists at the Zydus Research Centre. The biosimilar is the first to be launched by any company in the world and is a fingerprint match with the originator in terms of safety, purity and potency of the product. The biosimilar of Adalimumab is a part of Zydus' robust biologics programme which has the largest number of monoclonal antibodies under development in India. The group's R&D pipeline which comprises 24 biologics includes biosimilars and three novel biologics. These biologics are being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke.

Adalimumab, the fully human anti-TNF alpha monoclonal antibody, was first approved globally in 2002 and has since then been the most preferred therapy to treat patients suffering from auto immune disorders. However, the therapy was not available to patients in India.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia